Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Non-Current Deffered Revenue: 2019-2020

Historic Non-Current Deffered Revenue for Burning Rock Biotech (BNR) over the last 1 years, with Dec 2020 value amounting to $40,000.

  • Burning Rock Biotech's Non-Current Deffered Revenue fell 71.55% to $40,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $40,000, marking a year-over-year decrease of 71.55%. This contributed to the annual value of $40,000 for FY2020, which is 72.13% down from last year.
  • Latest data reveals that Burning Rock Biotech reported Non-Current Deffered Revenue of $40,000 as of Q4 2020, which was up 2.56% from $39,000 recorded in Q3 2020.
  • Burning Rock Biotech's Non-Current Deffered Revenue's 5-year high stood at $140,604 during Q4 2019, with a 5-year trough of $37,000 in Q2 2020.
  • In the last 2 years, Burning Rock Biotech's Non-Current Deffered Revenue had a median value of $39,500 in 2020 and averaged $64,151.
  • Data for Burning Rock Biotech's Non-Current Deffered Revenue shows a maximum YoY plummeted of 71.55% (in 2020) over the last 5 years.
  • Quarterly analysis of 2 years shows Burning Rock Biotech's Non-Current Deffered Revenue stood at $140,604 in 2019, then plummeted by 71.55% to $40,000 in 2020.
  • Its last three reported values are $40,000 in Q4 2020, $39,000 for Q3 2020, and $37,000 during Q2 2020.